Dengue vaccine
VACCINE TYPE
- Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
- Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
- The vaccine is built on a yellow fever backbone component.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 19, 2023
Citation
Dzintars, Kathryn. "Dengue Vaccine." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545319/all/Dengue_vaccine.
Dzintars K. Dengue vaccine. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545319/all/Dengue_vaccine. Accessed December 8, 2023.
Dzintars, K. (2023). Dengue vaccine. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545319/all/Dengue_vaccine
Dzintars K. Dengue Vaccine [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 December 08]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545319/all/Dengue_vaccine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dengue vaccine
ID - 545319
A1 - Dzintars,Kathryn,PharmD, BCPS
Y1 - 2023/01/19/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545319/all/Dengue_vaccine
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -